Immunotherapy of AML

Cancer Treatment and Research

Volumn 145, Issue , 2010, Pages 237-255

  Alatrash, Gheath ^b   Molldrem, Jeffrey J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD33 ANTIGEN; DENDRITIC CELL VACCINE; GEMTUZUMAB OZOGAMICIN; PEPTIDE VACCINE; RHAMM VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VALYLLEUCYLGLUTAMINYLGLUTAMYLLEUCYLASPARAGINYLVALYLTHREONYLVALINE VACCINE; WT1 VACCINE; AMINOGLYCOSIDE; CANCER VACCINE; CYTOKINE; GEMTUZUMAB; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MAINTENANCE THERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MOUSE; TRANSPLANTATION;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MICE; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956152185     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69259-3_14     Document Type: Review

References (130)

1. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921-1925.
2. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4() donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671-3680.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
4. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3:241-252.
5. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
6. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997;80:2205-2209.
7. Blaise D, Attal M, Pico JL, et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma. 1997;25:469-478.
8. Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw. 2000;11:91-98.
9. Borden EC, Hogan TF, Voelkel JG. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res. 1982;42:4948-4953.
10. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503-3521.
11. Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res. 2006;35:263-278.
12. Boyer MW, Vallera DA, Taylor PA, et al. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8T-cell line with potent in vivo graft-versus-leukemia properties. Blood. 1997;89:3477-3485.
13. Braud VM, Allan DS, OCallaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
14. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846-6850.
15. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegeners granulomatosis (WG). Clin Exp Immunol. 1994;98:448-453.
16. Buggins AG, Lea N, Gaken J, et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood. 1999;94:3479-3490.
17. Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, Hirst WJ. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol. 2001;167:6021-6030.
18. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-400.
19. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
20. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [see comment]. N Engl J Med 1649;339:1649-1656.
21. Chan L, Hardwick NR, Guinn BA, et al. An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother. 2006;55:1017-1024.
22. Chomienne C, Ballerini P, Balitrand N, et al. The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia. 1990;4:802-807.
23. Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997;100:855-866.
24. Collins RH, Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
25. Datta AR, Barrett AJ, Jiang YZ, et al. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 1994;14:517-524.
26. Dengler R, Munstermann U, al-Batran S, et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol. 1995;89:250-257.
27. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410-414.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
29. Entwistle J, Zhang S, Yang B, et al. Characterization of the murine gene encoding the hyaluronan receptor RHAMM. Gene 1995;163:233-238.
30. Exley M, Garcia J, Wilson SB, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 2000;100:37-47.
31. Fais F, Morabito F, Stelitano C, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer. 2004;109:402-411.
32. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003;31:743-751.
33. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
34. Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE. Allospecific CD8Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol. 1996;157:4811-4821.
35. Franssen CF, Stegeman CA, Kallenberg CG, et al. Antiproteinase 3-and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000;57:2195-2206.
36. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002;3:867-874.
37. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
38. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120:646-652.
39. Ganser A, Heil G, Seipelt G, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol. 2000;79:30-35.
40. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702-3709.
41. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-4343.
42. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;84:3603-3612.
43. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol. 1996;8:96-102.
44. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21:573-583.
45. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
46. Greiner J, GiannopoulosK, Li L, et al. RHAMM/CD168-R3 Peptide vaccination of HLA-A2 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). American Society of Hematology Annual Meeting, 2005;106. Abstract 2781.
47. Greiner J, Li L, Ringhoffer M, Barth TF, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8 T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood. 2005;106:938-945.
48. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Childrens Leukaemia Working Parties. Blood. 1998;92:2322-2333.
49. Gutterman JU, Hersh EM, Rodriguez V, et al. Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet. 1405;2:1405-1409.
50. Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell. 1995;82:19-26.
51. Hambach L, Nijmeijer BA, Aghai Z, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 2006;20:371-374.
52. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287.
53. Hayakawa Y, Godfrey DI, Smyth MJ. Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem. 2004;11:241-252.
54. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA. 2003;100:9464-9469.
55. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science. 1981;214:24-30.
56. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematol Am Soc Hematol Educ Program. 2003;331-349.
57. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms tumor suppressor gene WT1. Cancer Res. 1995;55:5386-5389.
58. Hiesse C, Larue JR, Kriaa F, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: singlecenter analysis of a 20-year period in 1600 patients. Transplant Proc. 1995;27:2450-2451.
59. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
60. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 1795;356:1795-1799.
61. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 1910;11:1910-1917.
62. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005;19:2195-2202.
63. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dellAdulto. Br J Haematol. 1998;102:1344-1353.
64. Keilholz U, Letsch A, Asemissen A, et al. Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia. ASCO Ann Meet Proc. 2006;24:2511.
65. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277-4283.
66. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 1997;9:139-145.
67. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
68. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442-1452.
69. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol. 1996;157:4741-4745.
70. Lee JJ, Kook H, Park MS, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher. 2004;19:66-70.
71. Li Y, Li H, Wang MN, et al. Suppression of leukemia expressing wild-type or ITDmutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood. 2004;104:1137-1144.
72. Lindmark A, Gullberg U, Osson I. Processing and intracellular transport of cathepsin G and neutrophil elastase in the leukemic myeloid cell line U-937-modulation by brefeldin A, ammonium chloride, and monensin. J Leukoc Biol. 1994;55:50-57.
73. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
74. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graftversus-host disease. Blood. 1995;86:1261-1268.
75. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.
76. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175-178.
77. Maraninchi D, Vey N, Viens P, et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma. 1998;31:343-349.
78. Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stemcell transplantation.Haematologica. 2007;92:72-80.
79. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742-2747.
80. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
81. Mathe G, Amiel JL, Schwarzenberg L, et al. Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemic effects. Blood. 1965;25:179-196.
82. Mathe G, Schwarzenberg L, Delgado M, De Vassal F. Active immunotherapy trials on acute lymphoid leukemia lymphosarcoma and acute myeloid leukemia. Eur J Cancer. 1977;13:445-455.
83. Meloni G, Foa R, Vignetti M, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood. 1994;84:2158-2163.
84. Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma. 1996;21:429-435.
85. Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am. 1997;3 (suppl 1):S43-47.
86. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17:1068-1077.
87. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29:1157-1168.
88. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-3057.
89. Miller JS, Tessmer-Tuck J, Pierson BA, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant. 1997;3:34-44.
90. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675-2681.
91. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
92. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies [see comment]. J Pediatr. 1995;126:1-10.
93. Mulford DA, Jurcic JG. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2004;4:95-105.
94. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versustumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev. 1997;157:167-176.
95. Mutis T, Ghoreschi K, Schrama E, et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biol Blood Marrow Transplant. 2002;8:412-419.
96. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341.
97. Nakagawa R, Motoki K, Ueno H, et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 1998;58:1202-1207.
98. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885-13890.
99. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72:314-321.
100. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol. 17:297-329.
101. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol. 1997;159:2222-2231.
102. Rao NV, Rao GV, Marshall BC, Hoidal JR. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. J Biol Chem. 1996;271:2972-2978.
103. Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 1996;10:1874-1882.
104. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
105. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
106. Schirrmann T, Pecher G. Specific targeting of CD33() leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res. 2005;29:301-306.
107. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-3750.
108. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia [see comment]. Lancet. 1996;348:587-591.
109. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
110. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
111. Shimizu K, Hidaka M, Kadowaki N, et al. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide- loaded murine dendritic cells. J Immunol. 2006;177:3484-3492.
112. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia. 2005;19:2215-2222.
113. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083.
114. Spada FM, Borriello F, Sugita M, Watts GF, Koezuka Y, Porcelli SA. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol. 2000;30:3468-3477.
115. Spisek R, Chevallier P, Morineau N, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 2002;62:2861-2868.
116. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232-1240.
117. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21:66-71.
118. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154-1163.
119. Timonen T, Ortaldo JR, Herberman RB. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981;153:569-582.
120. Timonen T, Saksela E. Isolation of humanNKcells by density gradient centrifugation. J Immunol Methods. 1980;36:285-291.
121. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol. 1999;163:2387-2391.
122. Tsimberidou AM, Giles FJ, Estey E, OBrien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132:398-409.
123. Tsuboi A, Oka Y, Ogawa H, et al. Constitutive expression of the Wilms tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res. 1999;23:499-505.
124. Tsuji T, Yasukawa M, Matsuzaki J, et al. Generation of tumor-specific, HLA class Irestricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood. 2005;106:470-476.
125. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-763.
126. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197-3204.
127. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000;106:705-714.
128. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005;106:3062-3067.
129. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103:1652-1658.
130. Zeis M, Siegel S, Wagner A, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 2003;170:5391-5397.